A joint supplement reported by roughly 8% of patients in a University of Florida Health records review was linked to a 25% higher likelihood that mild cognitive impairment would progress to dementia. The same analysis reported a separate 25% higher mortality risk among people who already had dementia. Both figures describe associations in hospital records, and the authors say so in their own caveat.
The work comes from the University of Florida, with Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation at the McKnight Brain Institute, among the lead researchers. Tara R. Hawkinson is first author, and the author list includes Matt Gentry, who chairs the Department of Biochemistry and Molecular Biology, along with Yi Guo, Jiang Bian and Stefan Prokop. The paper first appeared on 9 June 2026 under DOI 10.1038/s42255-026-01538-4; ScienceDaily republished the university’s summary on 27 September.
Health records, brain tissue and a mouse model
The clinical arm of the study is a retrospective analysis of de-identified UF Health electronic records spanning 2012 to 2024. In the Nature Metabolism paper, glucosamine use was associated with a 25% higher likelihood that mild cognitive impairment would progress to dementia. According to the university’s release, the analysis cited 1,896 people with Alzheimer’s disease and related dementias and 2,750 with mild cognitive impairment, with roughly 8% of both groups reporting glucosamine use.
Records alone were not the whole project. The team also examined human brain tissue and ran mouse experiments focused on hyperglycosylation, the excessive attachment of sugar structures to proteins through abnormal metabolic pathways in Alzheimer’s brains. The idea Sun’s group is pursuing is that this sugar-tagging may drive neurodegeneration rather than protect against it, which would make a widely sold amino-sugar supplement a plausible candidate for feeding the process. The laboratory work supplies a mechanism worth testing; it does not convert the record-review result into proof.
Two separate 25% figures
The 25% in question concerns progression: among people with mild cognitive impairment, glucosamine use went with a 25% higher likelihood of moving on to dementia. The mortality number belongs to a different group and a different outcome. In people with established dementia, glucosamine use was associated with a 25% higher mortality risk, an effect the release says was not seen in the mild-impairment group on its own. Two figures of identical size sit side by side in the same paper, which makes them easy to merge in a headline, so the two are kept apart here.
Both are relative figures. The university’s summary reports no absolute progression rates for users and non-users, so the 25% cannot be translated into how many extra people per thousand moved from mild impairment to dementia.
Limits that an observational design leaves in place
Sun framed the clinical stakes in the university’s account, reproduced by Neuroscience News: “A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse.” That sentence is a hypothesis about a population, and the same coverage records Gentry calling the electronic health record data “very provocative” while stressing that they show association, not causation. Sun also argued that altered metabolism could complement existing approaches built around amyloid plaques and tangles, a reason the team treats the sugar-tagging pathway as a drug target in its own right and not only as a caution about one supplement.
The authors’ own wording, as carried in the ScienceDaily summary, is direct: “The electronic health record findings do not show that glucosamine itself causes dementia to progress. Observational studies can reveal associations, but other differences between people who take a supplement and those who do not may contribute to the results.” Gentry made the same point in the release, calling the finding “an association and not proof of causality” while adding that “it does raise an important clinical question.”
Confounding is the standard difficulty with supplement studies built on health records. Why a person takes the product matters, since glucosamine is typically bought for joint pain, and so does how closely that person is monitored, because a clinician has to note the supplement for it to appear in the record at all. Any of those differences could shift who is counted as progressing, and a records review cannot sort them out the way randomization does.
The researchers say a controlled human clinical trial would be needed to determine whether glucosamine directly accelerates Alzheimer’s progression. Until one is run, the documented facts are narrow: a 25% higher progression likelihood and a 25% higher mortality risk in two separate UF Health groups, from a Nature Metabolism paper whose senior authors describe it as a question for clinicians and not an answer.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
